AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01020279
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
Trial: NCT00697515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once-daily for one week during the adult workplace environment setting
Trial: NCT00940212
Drug: AZD2423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, single administration
Trial: NCT00940212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration and single dose
Trial: NCT02436759
Drug: RVL-1201 Vehicle Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVL-1201 Vehicle Placebo
Trial: NCT02292290
Drug: Sulfonylurea or Pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition to Metformin
Trial: NCT03054857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
Trial: NCT00146146
Drug: testosterone undecanoate alone
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg/12 weeks
Trial: NCT00146146
Drug: testosterone undecanoate plus letrozole
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TU 1000 mg/12 weeks Letrozole 2.5 mg/day
Trial: NCT00146146
Drug: testosterone undecanoate plus dutasteride
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TU 1000 mg/12weeks Dutasteride 0.5 mg/day
Trial: NCT00464568
Drug: GSK256066
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04231682
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
Trial: NCT02397421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
Trial: NCT00405587
Drug: PLX4032
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules administered BID
Trial: NCT02419742
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AC-TH regimen: Cyclophosphamide 600 mg/m\^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
Trial: NCT02419742
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Doxorubicin 60 mg/m\^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
Trial: NCT00729027
Drug: 25 mg/day AVE5530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)
Trial: NCT00729027
Drug: 50 mg/day AVE5530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)
Trial: NCT00729027
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)
Trial: NCT01411709
Drug: Vitano
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 200mg tablets per day for 14 days
Trial: NCT01404923
Drug: anti spasmodic agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: best standard of care prescriptions
Trial: NCT03489772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00684476
Drug: venom immunotherapy
RxNorm normalized name: bushmaster venom
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02905682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03491995
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin
Trial: NCT03491995
Drug: Classic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, amoxycillin, clarithromycin
Trial: NCT00523250
Drug: AR-102 0.003% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00523250
Drug: AR-102 0.005% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00523250
Drug: AR-102 0.01% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00617097
Drug: ketorolac and lidocaine
RxNorm normalized name: phenylephrine and ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paracervical block with ketorolac and lidocaine
Trial: NCT00523250
Drug: AR-102 0.03% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03060993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
Trial: NCT00140153
Drug: testosterone gel (Androgel)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02565147
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin is an anticoagulant.
Trial: NCT01142310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01275274
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
Trial: NCT01153243
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators will give control group 12 weeks of 1 placebo pill every week.
Trial: NCT02177448
Drug: BIBR277 medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02177448
Drug: Placebo matching BIBR277
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01008761
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
Trial: NCT01324388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT03837561
Drug: Cunox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
Trial: NCT01008761
Drug: Suspension Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
Trial: NCT01085097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Trial: NCT03149107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
Trial: NCT03384329
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Pills
Trial: NCT03345589
Drug: 18-22mg/kg/d Ursodeoxycholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18-22mg/kg/d Ursodeoxycholic
Trial: NCT03345589
Drug: 13-15mg/kg/d Ursodeoxycholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-15mg/kg/d Ursodeoxycholic
Trial: NCT03963115
Drug: Epinephrine or normal saline
RxNorm normalized name: Rosula NS Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epinephreine or normal saline coated syringe before drawing allergen for injection.
Trial: NCT00780325
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
Trial: NCT00780325
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
Trial: NCT00780325
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
Trial: NCT04225299
Drug: TOOKAD®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOOKAD® -VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
Trial: NCT00124969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg
Trial: NCT01147705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same appearance/dosing as active drug.
Trial: NCT01708174
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.
Trial: NCT00937872
Drug: 250 mg SRT2104 Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
Trial: NCT02225756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration for a short time of placebo
Trial: NCT03013556
Drug: Group A, TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF for 96 weeks
Trial: NCT03560531
Drug: ZN-c5
RxNorm normalized name: dipentaerythrityl hexa C5-10 acid esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZN-c5 is a study drug
Trial: NCT03011307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spinal injection of placebo
Trial: NCT04628676
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine is added to the irrigation fluid used in arthroscopic shoulder surgery.
Trial: NCT00484939
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
Trial: NCT00745290
Drug: SKY0402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg SKY0402 (study drug).
Trial: NCT03014323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 capsule twice a day for 4 weeks
Trial: NCT04087187
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will be given AZD5718 Dose A tablet once daily
Trial: NCT04087187
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given AZD5718 Dose B tablet once daily
Trial: NCT01067222
Drug: BF2.649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BF2.649 oral capsules at 10 or 20 or 40 mg per day
Trial: NCT01067222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules, 4 capsules per day
Trial: NCT01344187
Drug: placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0% riboflavin ophthalmic solution
Trial: NCT02404285
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
Trial: NCT02963337
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
Trial: NCT02963337
Drug: combined spinal-epidural analgesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
Trial: NCT01060904
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 IV every 2 weeks
Trial: NCT02556333
Drug: FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
Trial: NCT05096143
Drug: ACEi/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who were prescribed with Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
Trial: NCT00749788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets, oral, 30 minutes after the start of the morning meal
Trial: NCT02467569
Drug: Hemay020
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04780854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the placebo group will be administered metformin free tablet as placebo twice daily
Trial: NCT00990496
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2
Trial: NCT00901758
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
Trial: NCT00713336
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD4054 10mg Tablet
Trial: NCT00713336
Drug: ZD4054 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets
Trial: NCT00713336
Drug: ZD4054 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets
Trial: NCT00713336
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg tablet
Trial: NCT00713336
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg tablet
Trial: NCT03404479
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For 12 weeks, administered twice a day by oral.
Trial: NCT03492255
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
Trial: NCT00708942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppository, for 3-7 hours application
Trial: NCT00708942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment for 5 hours application
Trial: NCT00988507
Drug: Ferroquine (SSR97193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT00988507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT04835025
Drug: PD-1/PD-L1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In non-small cell lung cancer, patients with brain metastases received radiotherapy for brain lesions and immunotherapy (including sequential and concurrent model). Those patients would enter the trial group; After patients experiencing PD in this group, follow-up treatment until tumor progression again or death
Trial: NCT02443012
Drug: Topical Gutt Nepafenac 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Nepafenac as an adjunct to focal/grid laser
Trial: NCT03631901
Drug: oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both melatonin and diazepam were given only during the febrile illness.
Trial: NCT02540460
Drug: LCB01-0371 800mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCB01-0371 800mg
Trial: NCT02540460
Drug: LCB01-0371 800mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCB01-0371 800mg BID
Trial: NCT02540460
Drug: LCB01-0371 1200mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCB01-0371 1200mg BID
Trial: NCT02540460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03341832
Drug: NVP-1203-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose for 7 days
Trial: NCT03341832
Drug: NVP-1203 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose for 7 days
Trial: NCT03341832
Drug: NVP-1203-R placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose for 7 days
Trial: NCT00239707
Drug: GIP
RxNorm normalized name: GIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-time 20 ng/kg/min infusion over 3 hours
Trial: NCT00239707
Drug: Modified GIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl
Trial: NCT00239707
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one-time infusion over 3 hours
Trial: NCT03226431
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
Trial: NCT02691299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
Trial: NCT01769040
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03730714
Drug: Local Anesthetic, Epinephrine and Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
Trial: NCT03730714
Drug: Local Anesthetic, Epinephrine, Morphine and Surgicel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
Trial: NCT03730714
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 0.9% to soak the surgicel according to the planned technique
Trial: NCT03281954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose.
Trial: NCT00056030
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00056030
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00393991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
Trial: NCT00545857
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
Trial: NCT00969163
Drug: testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks